Examining various targets, including cholinergic dysfunction, glutamatergic excitotoxicity, amyloid and tau aggregation, neuroinflammation, and synaptic degradation, will facilitate a deeper understanding and connection with AD. The gene discussed is MAPT; the disease is Alzheimer disease.